Fidest – Agenzia giornalistica/press agency

Quotidiano di informazione – Anno 31 n° 259

54th ASCO Annual Meeting in Chicago

Posted by fidest press agency su martedì, 22 maggio 2018

Chicago. ONCODESIGN (Paris:ALONC) (ALONC – FR0011766229), a biopharmaceutical company specializing in precision medicine, announces the publication of an abstract presenting the interim results of the first 12 patients participating in its clinical study with its first radiotracer, for the 54th annual meeting of ASCO (American Society of Clinical Oncology) in Chicago, USA.The primary objective of this clinical study is to assess the clinical interest of the 18F-ODS2004436 radiotracer in PET1 imaging, by determining its sensitivity and specificity in patients with non-small cell lung cancer.In the first stage of the clinical study, 8 patients with EGFR mutations received an injection of the radiotracer. Results showed that the radiotracer did reach and bind to its target, whether a primary or metastatic tumor. The signal reduction after one week’s treatment confirmed the presence of the therapeutic molecule within the tumor. In two of these patients, the radiotracer also alerted the oncologist to the presence of brain metastases, which had gone unnoticed until thenThe results presented at ASCO also include the first four patients recruited in the study’s second stage. These initial results in patients with no EGFR mutation validate the specificity of the radiotracer.
“This 18F-fluorine-labeled radiotracer is a molecule generated using Oncodesign’s Nanocyclix® technology. These interim results reported for ASCO are promising and confirm the preclinical results,” said Philippe Genne, founder, Chairman and CEO of Oncodesign. “The opportunity to present these results at the ASCO annual meeting, the leading event for the international oncology community, is extremely important for Oncodesign and for the visibility of this highly innovative program able to guide clinicians on treatment selection.” Every year, 30,000 oncology experts attend the ASCO meeting to review the latest advances in cancer research. Researchers, physicians and caregivers come to share the results of their clinical and translational work.


Inserisci i tuoi dati qui sotto o clicca su un'icona per effettuare l'accesso:


Stai commentando usando il tuo account Chiudi sessione /  Modifica )

Google photo

Stai commentando usando il tuo account Google. Chiudi sessione /  Modifica )

Foto Twitter

Stai commentando usando il tuo account Twitter. Chiudi sessione /  Modifica )

Foto di Facebook

Stai commentando usando il tuo account Facebook. Chiudi sessione /  Modifica )

Connessione a %s...

%d blogger hanno fatto clic su Mi Piace per questo: